Aug 2026· Journal of Clinical Epidemiology· Vol 199, pp.
112442
· 0 citations
Medicine
TL;DR
This pilot study provides promising insights for improving the costs and duration of clinical trials by combining experimental arms with specialized cancer registry data.
Abstract
Background
Randomized clinical trials are becoming very challenging to perform in oncology both in rare cancers and in more common cancers, fragmented according to molecular characteristics.
Objective
In this proof of concept, we tested the feasibility of using data from a specialized digestive cancer registry as an external control arm in two phase III randomized clinical trials.
Methods
To emulate PETACC-8, the generated hybrid control arm comprised a constrained proportion of external patients. PRODIGE-13 was emulated through a fully external control arm and through a hybrid control arm containing 50% of external patients. Propensity score was used either for inverse probability of treatment weighting or for patients matching. Absolute Standardized Mean Differences tested the balance between arms. Overall Survival was estimated using Kaplan-Meier estimator and compared using the Logrank test.
Results
For both trials, Registry data were considered fit-for-use despite different settings and patients baseline characteristics were balanced between the emulated trial arms. In the emulated PETACC-8 trial, the overall survivals of the hybrid control arms were not different from that of the control and experimental arms. In the emulation of PRODIGE-13, survival analyses showed that the fully external control arm mimicked the control arm and that the hybrid arm with 50% external data mimicked both control and experimental arms. Pending appropriate patient selection, the data from the Registry allowed to generate external control arms mimicking control arms.
Conclusion
This pilot study provides promising insights for improving the costs and duration of clinical trials by combining experimental arms with specialized cancer registry data.
ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC, and supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
M. Raeisi, T. André, Q. Shi et al.· Journal of the National Canc...· 0 citations
INTRODUCTION
Randomized controlled trials (RCTs) are the gold standard in oncology for the discovery of new therapeutic approaches and treatment management. As medicine takes a more patient-centered approach, patient-reported outcomes (PROs) have become imperative, particularly in clinical trials. The need for standard...
A. Douglas, Ty Moore, Griffin K. Hughes et al.· Clinical Breast Cancer· 0 citations
Well-designed prospective, longitudinal registries collecting broad and deep real-world data complement RCTs, inform Health Technology Assessments, and fill knowledge gaps by creating treatment transparency, addressing evidence gaps, and providing realistic outcome expectations for the heterogeneous populations in rout...
M. Jänicke, S. Dille, M. Frank et al.· ESMO real world data and dig...· 0 citations
BACKGROUND
Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence fr...
C. Bommier, J. Dixon, M. Maurer et al.· Journal of Clinical Epidemio...· 0 citations
OBJECTIVES
To characterize trial design, endpoint emphasis and public results reporting in interventional laryngeal cancer studies.
DESIGN
Registry-based descriptive study of trial records.
SETTING
ClinicalTrials.gov; records were retrieved on 28 July 2025.
PARTICIPANTS
Interventional trials retrieved using the t...
Jin Wang, Jun-Feng Wu, Zi-Qi Yang et al.· Clinical Otolaryngology· 0 citations
AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
The evolution of targeted therapies in pancreatic ductal adenocarcinoma (PDAC) may pose challenges for future clinical research. Assigning patients to standard-of-care chemotherapies in randomized controlled trials (...
Ruthie Davi· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.